These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35184708)

  • 1. Fluoroquinolone-induced Glycaemic Aberrations: Could Quinolones be Repurposed to Serve as New Antidiabetic Agents?
    Ayodele O; Khanye S; Mothibe M; Sibiya N
    Curr Rev Clin Exp Pharmacol; 2023; 18(1):12-21. PubMed ID: 35184708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
    Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
    Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice.
    Hori S; Kizu J; Kawamura M
    J Infect Chemother; 2006 Apr; 12(2):109-11. PubMed ID: 16648952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of quinolone-resistant mechanisms in a lab-selected Salmonella enterica typhimurium mutant.
    Gu Y; Xu X; Lin L; Ren X; Cui X; Hou X; Cui S
    Microb Drug Resist; 2013 Feb; 19(1):15-20. PubMed ID: 23013383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
    Nathania I; Nainggolan IM; Yasmon A; Nusatia ACM; Tjoa E; Gunardi WD; Moehario LH
    BMC Microbiol; 2022 Oct; 22(1):250. PubMed ID: 36253712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolone: a versatile therapeutic compound class.
    Dube PS; Legoabe LJ; Beteck RM
    Mol Divers; 2023 Jun; 27(3):1501-1526. PubMed ID: 36527518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Growing incidence of nalidixic acid resistance and sensitivity to quinolones in Salmonella typhimurium strains isolated from man or animal].
    Heurtin-Le Corre C; Donnio PY; Bonnier M; Travert MF; Lacourt A; Avril JL
    Pathol Biol (Paris); 1998 Oct; 46(8):587-90. PubMed ID: 9871929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions.
    Cavaco LM; Aarestrup FM
    J Clin Microbiol; 2009 Sep; 47(9):2751-8. PubMed ID: 19571019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels.
    Saraya A; Yokokura M; Gonoi T; Seino S
    Eur J Pharmacol; 2004 Aug; 497(1):111-7. PubMed ID: 15321742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control: a balancing act or a different approach?
    Fava S
    Curr Diabetes Rev; 2014 Mar; 10(2):124-30. PubMed ID: 24745817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety concerns with fluoroquinolones.
    Mehlhorn AJ; Brown DA
    Ann Pharmacother; 2007 Nov; 41(11):1859-66. PubMed ID: 17911203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of high-level quinolone resistance in Campylobacter jejuni.
    Gootz TD; Martin BA
    Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced hypoglycaemia: an update.
    Ben Salem C; Fathallah N; Hmouda H; Bouraoui K
    Drug Saf; 2011 Jan; 34(1):21-45. PubMed ID: 20942513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.